A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Young Volunteers, Healthy Elderly Volunteers

In brief

This is a single dose study in healthy male and female (of non-child bearing potential) volunteers, to assess the safety, effects on the body, and blood and urine drug levels of AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease

Key facts

Study ID

NCT01739647

Run by

AstraZeneca

People needed

72

Starts

2012-12-01

Expected to finish

2013-05-01

Last updated by the study team

2013-08-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female (of non-childbearing potential) subjects
• Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg

You may not qualify if…

• History or presence of psychiatric disease/condition, GI, renal, hepatic, cardiovascular, psychiatric, or retinal diseases or disorders
• History of neurological disease, including seizures, recent memory impairment, or clinically significant head injury
• History of use of antipsychotic drugs , or chronic use of antidepressant or anxiolytic drugs
• Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other nicotine products

Where it is running

• Research Site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.